GERON CORP Interest Expense
GERON CORP (GERN) reported Interest Expense of $18.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2025-02-27
- GERON CORP interest expense for the quarter ending 2024-12-31 was $8.71M, a 275.10% increase year-over-year.
- GERON CORP interest expense for the quarter ending 2024-09-30 was $3.05M, a 47.43% increase year-over-year.
- GERON CORP interest expense for the quarter ending 2024-06-30 was $3.32M, a 65.70% increase year-over-year.
- GERON CORP interest expense for the quarter ending 2024-03-31 was $3.43M, a 78.62% increase year-over-year.
- GERON CORP interest expense for fiscal 2024 was $18.50M, a 122.62% increase from fiscal 2023.
- GERON CORP interest expense for fiscal 2023 was $8.31M, a 20.78% increase from fiscal 2022.
- GERON CORP interest expense for fiscal 2022 was $6.88M, a 84.01% increase from fiscal 2021.
- GERON CORP interest expense for fiscal 2021 was $3.74M, a 392.11% increase from fiscal 2020.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $8.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $11.75M derived: sum of 2 quarters · filed 2025-02-27 | $15.07M derived: sum of 3 quarters · filed 2025-02-27 | $18.50M 10-K · filed 2025-02-27 |
| 2024-09-30 | $3.05M 10-Q · filed 2024-11-07 | $6.37M derived: sum of 2 quarters · filed 2024-11-07 | $9.80M 10-Q · filed 2024-11-07 | $12.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | $3.32M 10-Q · filed 2024-08-08 | $6.75M 10-Q · filed 2024-08-08 | $9.07M derived: sum of 3 quarters · filed 2025-02-27 | $11.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $3.43M 10-Q · filed 2024-05-02 | $5.75M derived: sum of 2 quarters · filed 2025-02-27 | $7.82M derived: sum of 3 quarters · filed 2025-02-27 | $9.82M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.39M derived: sum of 2 quarters · filed 2025-02-27 | $6.39M derived: sum of 3 quarters · filed 2025-02-27 | $8.31M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.07M 10-Q · filed 2024-11-07 | $4.07M derived: sum of 2 quarters · filed 2024-11-07 | $5.99M 10-Q · filed 2024-11-07 | $8.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.00M 10-Q · filed 2024-08-08 | $3.92M 10-Q · filed 2024-08-08 | $5.93M derived: sum of 3 quarters · filed 2025-02-27 | $7.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.92M 10-Q · filed 2024-05-02 | $3.93M derived: sum of 2 quarters · filed 2025-02-27 | $5.74M derived: sum of 3 quarters · filed 2025-02-27 | $7.33M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.82M derived: sum of 2 quarters · filed 2025-02-27 | $5.40M derived: sum of 3 quarters · filed 2025-02-27 | $6.88M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.82M 10-Q · filed 2023-11-02 | $3.40M derived: sum of 2 quarters · filed 2023-11-02 | $4.88M 10-Q · filed 2023-11-02 | $6.01M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $1.58M 10-Q · filed 2023-08-03 | $3.06M 10-Q · filed 2023-08-03 | $4.20M derived: sum of 3 quarters · filed 2024-02-28 | $5.25M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.48M 10-Q · filed 2023-05-11 | $2.61M derived: sum of 2 quarters · filed 2024-02-28 | $3.67M derived: sum of 3 quarters · filed 2024-02-28 | $4.48M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.19M derived: sum of 2 quarters · filed 2024-02-28 | $3.00M derived: sum of 3 quarters · filed 2024-02-28 | $3.74M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.06M 10-Q · filed 2022-11-07 | $1.86M derived: sum of 2 quarters · filed 2022-11-07 | $2.60M 10-Q · filed 2022-11-07 | $3.36M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $804.00K 10-Q · filed 2022-08-11 | $1.55M 10-Q · filed 2022-08-11 | $2.30M derived: sum of 3 quarters · filed 2023-03-16 | $2.31M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $743.00K 10-Q · filed 2022-05-09 | $1.50M derived: sum of 2 quarters · filed 2023-03-16 | $1.50M derived: sum of 3 quarters · filed 2023-03-16 | |
| 2020-12-31 | $754.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $760.00K derived: sum of 2 quarters · filed 2023-03-16 | $760.00K 10-K · filed 2023-03-16 | |
| 2020-09-30 | $6.00K 10-Q · filed 2021-11-09 | $6.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |